Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V-Endo
- Development stage
- Phase 2
- Lead developer
- Immunitor
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
V-Endo is an oral immunotherapy candidate developed by Immunitor Inc. for the treatment of endometriosis. The drug is a tableted preparation derived from hydrolyzed and heat-inactivated blood pooled from women diagnosed with endometriosis. Its mechanism of action is based on the principle of oral tolerance, where the ingestion of disease-associated antigens is intended to modulate the immune system, leading to anti-inflammatory effects and immune tolerance. V-Endo is designed to alleviate the chronic painful symptoms of endometriosis and potentially address associated infertility by reducing the underlying inflammatory processes.
- Brand names
- V-Endo
Beyond the preview
Go deeper on V-Endo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V-Endo.